PMID- 37650045
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230901
IS  - 1177-889X (Print)
IS  - 1177-889X (Electronic)
IS  - 1177-889X (Linking)
VI  - 17
DP  - 2023
TI  - A Health State Utility Study to Elicit Societal Values Associated with Pulmonary 
      Hypertension.
PG  - 2119-2130
LID - 10.2147/PPA.S400061 [doi]
AB  - AIM: Pulmonary hypertension (PH) is a rare, severe, and progressive pulmonary 
      vascular disease, which includes five subgroups with similar presentation. 
      Symptoms include dyspnea, and fatigue, and can significantly impact one's 
      health-related quality of life (HRQL). Although treatments are mainly medical, PH 
      group 4, chronic thromboembolic pulmonary hypertension (CTEPH), can be managed 
      with procedures, ie pulmonary endarterectomy (PEA) and balloon pulmonary 
      angioplasty (BPA). Currently, drugs in Europe are only approved for pulmonary 
      arterial hypertension (PAH), and CTEPH therefore the aim of this study was to 
      elicit novel societal health state utilities in the UK for PAH and CTEPH based on 
      disease severity, functional class (FC), clinical events, and treatment 
      procedures specifically for CTEPH. MATERIAL AND METHODS: Six health states were 
      defined: World Health Organization (WHO)-FC II, WHO-FC III, and WHO-FC IV 
      [defined by the New York Heart Association (NYHA)]; PH-related hospitalization; 
      and "BPA procedure and recovery" and "PEA surgery and recovery". Health states 
      were based on a targeted literature review and two rounds of interviews with 
      clinical experts (N = 4) and patients (N = 6). Draft health states were validated 
      in cognitive debriefing interviews with clinical experts (N = 3). Health states 
      were valued by the UK general public (n = 200), using a visual analogue scale 
      (VAS) and time trade-off (TTO) assessment with the lead time method. RESULTS: The 
      mean TTO values/utilities were 0.81 (FC II), 0.80 (BPA), 0.78 (PEA), 0.59 (FC 
      III), 0.28 (FC IV), and 0.25 (PH-related hospitalization). Each progression in FC 
      was associated with worse TTO scores. CONCLUSION: This study reports societal 
      utility values for PAH and CTEPH in the UK. It provides first utility estimates 
      for states such as BPA procedure and recovery, PEA surgery and recovery and 
      PH-related hospitalization for this population. The results show important 
      distinctions between FC, treatment procedures, and hospitalization, and the 
      significant burden of disease on HRQL.
CI  - (c) 2023 Nafees et al.
FAU - Nafees, Beenish
AU  - Nafees B
AD  - Patient-Reported Outcomes, Nafees Consulting Limited, London, UK.
FAU - de Freitas, Hayley M
AU  - de Freitas HM
AUID- ORCID: 0000-0002-2214-0851
AD  - Patient-Reported Outcomes, Nafees Consulting Limited, London, UK.
FAU - Beaudet, Amelie
AU  - Beaudet A
AUID- ORCID: 0000-0003-0535-672X
AD  - Global Market Access and Pricing, Actelion Pharmaceuticals Ltd, Allschwil, 
      Switzerland.
FAU - Todd, Eunju
AU  - Todd E
AD  - Janssen Global Commercial Strategy Organization, High Wycombe, UK.
FAU - Gin-Sing, Wendy
AU  - Gin-Sing W
AUID- ORCID: 0000-0002-6993-0965
AD  - Pulmonary Hypertension Service, Hammersmith Hospital, London, UK.
LA  - eng
PT  - Journal Article
DEP - 20230825
PL  - New Zealand
TA  - Patient Prefer Adherence
JT  - Patient preference and adherence
JID - 101475748
PMC - PMC10464901
OTO - NOTNLM
OT  - CTEPH
OT  - PAH
OT  - health-related quality of life
OT  - hospitalization
OT  - time trade-off
OT  - vignette
COIS- BN and HMdF were paid by Actelion Pharmaceuticals Ltd to conduct the research. AB 
      is an employee of Actelion Pharmaceuticals Ltd, a Janssen Pharmaceutical Company 
      of Johnson & Johnson. ET is an employee of Janssen Global Commercial Strategy 
      Organization, High Wycombe, UK. WGS has received honoraria for speaking and 
      consultation from Actelion Pharmaceuticals Ltd, a Janssen Pharmaceutical Company 
      of Johnson and Johnson, Acceleron, Bayer, Gossamer Bio, and MSD. The authors 
      report no other conflicts of interest in this work.
EDAT- 2023/08/31 06:42
MHDA- 2023/08/31 06:43
PMCR- 2023/08/25
CRDT- 2023/08/31 04:13
PHST- 2022/12/03 00:00 [received]
PHST- 2023/07/22 00:00 [accepted]
PHST- 2023/08/31 06:43 [medline]
PHST- 2023/08/31 06:42 [pubmed]
PHST- 2023/08/31 04:13 [entrez]
PHST- 2023/08/25 00:00 [pmc-release]
AID - 400061 [pii]
AID - 10.2147/PPA.S400061 [doi]
PST - epublish
SO  - Patient Prefer Adherence. 2023 Aug 25;17:2119-2130. doi: 10.2147/PPA.S400061. 
      eCollection 2023.